The history of antibiotics has repeated itself: drugs are discovered, but bacterial evolution can soon render them ineffective in treating infections. Resistance is fueled by injudicious use of existing drugs and compounded by a failure to develop novel new ones. Many major pharmaceutical companies have limited their investments in this antibiotic innovation, and only two new classes of these substances have reached the market in the past 30 years.
Pew’s work on antibiotics and innovation develops and supports policies that will spur innovation of new antibiotics to fight infections today and to ensure a healthy nation in the future.
Our WorkView All
While the threat of antibiotic resistance is growing, regulatory approval for drugs to treat highly resistant bacterial infections can be challenging. Only a small number of patients who contract such infections meet the requirements to participate in traditional clinical trials. It’s difficult for researchers to select and enroll subjects in clinical trials to study treatments for some of... Read More
On Dec. 10, 2014, Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT) introduced a bill to promote the development of much-needed antibiotics. Read More
Each November, the U.S. Centers for Disease Control and Prevention observes Get Smart About Antibiotics Week, a campaign to raise awareness of the escalating threat of antibiotic resistance and the measures that people can take to preserve the effectiveness of these critical drugs. Since last year’s Get Smart week, policymakers and other stakeholders in the U.S. and abroad have... Read More